Document is current
Any future updates will be listed below
-
Authors
Maksimos, Mina
Muz, Barbara
Magnani, John L.
Azab, Abdel Kareem https://orcid.org/0000-0002-6371-2780
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA094056, P30 CA091842)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Cancer Prevention and Research Institute of Texas (RR220088)
- License Information
-
More Information
Article History
Received: 30 November 2022
Revised: 29 March 2023
Accepted: 3 April 2023
First Online: 7 April 2023
Competing interests
: AKA received research funding to partially support this study from GlycoMimetics Inc. Moreover, AKA is the founder and owner of Targeted Therapeutics LLC and Cellatrix LLC; however, these have no contribution to this study. JLM is an employee and shareholder of GlycoMimetics Inc. Other authors declare no competing interests.
